Mexicanal physicians perception about hormonal therapy after the Women’s Health Initiative Study

Main Article Content

Sebastián Carranza-Lira
Javier Santos-González

Keywords

Hormone replacement therapy, WHI study, Climateric, Postmenopause

Abstract

Background: The medical opinion after WHI study has changed. The aim was to know the opinion of Mexican physicians about hormone therapy (HT) after the WHI study. 

Methods: there were given 14 questions to 463 physicians to know their opinion on HT according to risks, benefits, doses, indications and contraindications. Descriptive statistics were used for data analysis.

Results: Only 31 % begin HT after 60 years of age and 74 % considered that HT decreased osteoporosis risk; 73 % use progestin in women with uterus. 82 % did not believe that estrogen-progestin HT increased the possibility of endometrial cancer and 51 % believed that breast cancer possibility increased. The main indication for HT prescription was for bone loss diminution (51 %); 88 % considered that low dose HT was as effective as conventional dose. 

Conclusions: the use of HT has been modified by Mexican physicians after the WHI study.

Abstract 48 | PDF (Spanish) Downloads 6

References

Stouthamer N, Visser AP, Oddens BJ, Beusmans G, Hoogland H, van Ree JW, et al. Dutch general practitioners’ attitudes towards the climacteric and its treatment. Eur J Obstet Gynecol Reprod Biol 1993;50(2):147-152. 

 

O’Connor V, Del Mar C, Sheehan M, Fox-Young S, Cragg C, Siskind V. The menopause and hormone replacement therapy: Australian general practitioners’ self reported opinions, attitudes and behaviour. Fam Pract 1996;13(5):421-426.

 

Suárez-Almazor M, Homik JE, Messina D, Davis P. Attitudes and beliefs of family physicians and gynecologists in relation to the prevention and treatment of osteoporosis. J Bone Miner Res 1997;12 (7):1100-1107.

 

Ena G, Rozenberg S. Issues to debate on the Women’s Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod 2003;18(11):2245-2248. 

 

Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gómez MS, et al. Patients’ and clinicians’ attitudes after the Women’s Health Initiative study. Menopause 2004;11(1):57-61.

 

Ismail HM, Aleveritis E, Guha B, Olive K, Sloan S. Attitudes toward hormone replacement therapy in the new millennium: university physicians’ and patients’ perspectives. J Invest Med 2005;53(6):305-311.

 

Nassar AH, Essamad HM, Awwad JT, Khoury NG, Usta IM. Gynecologists’ attitudes towards hormone therapy in the post “Women’s Health Initiative” study era. Maturitas 2005;52(1):18-25.

 

Power ML, Zinberg S, Schulkin J. A survey of obstetricians-gynecologists concerning practice patterns and attitudes toward hormone therapy. Menopause 2006;13(3):434-441.

 

Kang BM, Kim MR, Park HM, Yoon BK, Lee BS, Cheng HW, et al. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women’s Health initiative study. Menopause 2006; 13(1):125-129. 

 

Grodstein F, Stampfer MJ, Colditz GA, Willet WC, Manson JE, Joffe M, et al Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336(25):1769-1775.

 

Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330(15):1062-1071.

 

Limouzin-Lamothe MA, Mairon N, Le Gal M. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994; 170(2):618-624.

 

Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case control study. Am J Epidemiol 1994;140(3):262-267.

 

Colditz GA, Hankinson SE, Hunter DJ, Willet WC, Manson J, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24): 1589-1593.

 

Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348(19):1839-1854.

 

Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, y col. Estrógeno más progestina y la incidencia de demencia y deterioro cognitivo leve en mujeres posmenopáusicas: el Estudio de memoria de la Iniciativa de salud de la mujer: un ensayo controlado aleatorizado. JAMA 2003; 289 (20): 2651-2662.

 

Grupo de Escritura para los Investigadores de la Iniciativa de Salud de la Mujer. Riesgo y beneficios del estrógeno más progestina en mujeres posmenopáusicas sanas. Principales resultados del ensayo controlado aleatorio de la Iniciativa de Salud de la Mujer. JAMA 2002; 288 (3): 321-333.

 

Carranza-Lira S, Fragoso DJ. Percepción de los ginecólogos en relación con la terapia